U.S. authorizes Pfizer COVID vaccine for children 12 to 15

Vaccine producer says in the trial of 2,260 adolescents aged 12 to 15, 100% efficacy in preventing the illness was reported; Coronavirus czar tells Ynet vaccination of children 'is sensitive and complex,' but hints Israel will follow FDA guidelines
Reuters|
U.S. regulators on Monday authorized Pfizer and BioNTech's COVID-19 vaccine for use in children as young as 12, widening the country's inoculation program as vaccination rates have slowed significantly.
  • Follow Ynetnews on Facebook and Twitter

  • The vaccine has been available under an emergency use authorization (EUA) to people as young as 16 in the United States. The vaccine makers said they had started the process for full approval for those ages last week.
    4 View gallery
    A young girl receives the coronavirus vaccine during clinical trials to test safety and efficacy in children
    A young girl receives the coronavirus vaccine during clinical trials to test safety and efficacy in children
    A young girl receives the coronavirus vaccine during clinical trials to test safety and efficacy in children
    (Photo: Reuters)
    The U.S. Food and Drug Administration said it was amending the EUA to include the millions of children aged 12 to 15.
    It is the first COVID-19 vaccine to be authorized in the United States for this age group, seen as an important step for getting children back into schools safely. U.S. President Joe Biden has asked states to make the vaccine available to the younger adolescents immediately.
    "Today's action allows for a younger population to be protected from COVID-19, bringing us closer to returning to a sense of normalcy and to ending the pandemic," Acting FDA Commissioner Dr. Janet Woodcock said in a statement. "Parents and guardians can rest assured that the agency undertook a rigorous and thorough review of all available data, as we have with all of our COVID-19 vaccine emergency use authorizations."
    4 View gallery
    The PfizerBioNTech vaccine approved for use in young teens by U.S. regulatory authorities
    The PfizerBioNTech vaccine approved for use in young teens by U.S. regulatory authorities
    The PfizerBioNTech vaccine approved for use in young teens by U.S. regulatory authorities
    (Photo: Reuters)
    Coronavirus czar Prof. Nachman Ash told Ynet on Sunday, before the FDA announcement, that the vaccination of children "is sensitive and complex," but added that he remained confident health professionals can make the right decisions.
    "I believe that the vaccines are safe and effective even among children," he said indicating Israel will follow FDA guidance and vaccinate its own population of children in the 12-15 age group. “Vaccinating children is important in order to prevent serious illness. Even if long-term side effects do occur, it is still safer than being sick,” Ash said.
    Most children with COVID-19 only develop mild symptoms or no symptoms at all. However, children are not without risk of becoming seriously ill, and they can still spread the virus. There have been outbreaks traced to sporting events and other activities for children in this age range.
    4 View gallery
    נחמן אש
    נחמן אש
    Coronavirus Czar Prof. Nachman Ash
    (Photo: GPO)
    Dr. William Gruber, a top vaccine scientist at Pfizer, said the EUA would help the United States reach further immunity and protect an age group that has not been completely spared from severe disease.
    "I hear from pediatricians and people out in the community, what a godsend this is going to be for the adolescent population who have been restricted in terms of sports activities, drama club, and the other sorts of things that naturally we want them to engage in," Gruber said.
    Vaccines are crucial to ending the pandemic. But many health officials are concerned vaccine hesitancy in some adults will be even more pronounced when it comes to their children.
    Parents may question the risks versus benefits, given the unknowns about the vaccines' long-term impact on childrens' development and data on how few young kids have been hit hard by COVID-19.
    The companies said in March that they found the vaccine produced robust antibody responses and was safe and effective in 12- to 15-year olds in a clinical trial.
    4 View gallery
     A child is tested for the coronavirus in February
     A child is tested for the coronavirus in February
    A child is tested for the coronavirus in February
    (Photo: Shutterstock)
    In the trial of 2,260 adolescents aged 12 to 15, there were 18 cases of COVID-19 in the group that got a placebo and none among those who received the actual vaccine, resulting in 100% efficacy in preventing the illness, the companies said at the time.
    Pfizer and BioNTech asked the FDA to expand their EUA to include the younger age group in early April.
    Comments
    The commenter agrees to the privacy policy of Ynet News and agrees not to submit comments that violate the terms of use, including incitement, libel and expressions that exceed the accepted norms of freedom of speech.
    ""